Bristol Myers Stock Gains 11.4% in a Year: Time to Buy or Sell?

It was a good year for biotech giant Bristol Myers (BMY) . Shares of the company have risen 11.4% against the industry’s 15.6% decline. The stock has also outperformed the sector but underperformed the S&P 500 during this period.The outperformance was more pronounced in the second half of the year, buoyed by strong quarterly performances, an increase in annual guidance and approval of new drugs.This stupendous rally after touching a 52-week low in July has enabled BMY to regain its lost territories. The sto ...